宮頸癌預后相關分子標志物的研究進展_《華西醫學》

作者：

張羽 , 杜小波 , 王晉 , 趙振華 , 任素容 , 周筱秋

綿陽市中心醫院腫瘤科（四川綿陽，621000）;

關鍵詞：

宮頸癌預后分子標志物研究進展

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

近年來惡性腫瘤相關標志物的研究已經成為腫瘤學科研工作的熱點，其中關于宮頸癌預后相關分子標志物的研究在國際上也取得了重要進展，本文對其這方面的進展作一綜述。

引用本文： 張羽,杜小波,王晉,趙振華,任素容,周筱秋. 宮頸癌預后相關分子標志物的研究進展. 華西醫學, 2012, 27(5): 783-785. doi: 復制

1.	Parkin DM, Bray F, Ferlay J, et al. Global Cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
2.	Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world[J]. J Clin Oncol, 2006, 24(14): 2137-2150.
3.	Bezerra AL, Martins MR, Bezerra SM, et al. ClassⅡ radical hysterectomy for stage Ⅰ-ⅡA cervix Cancer: prognostic factors associated to recurrence and survival in a Northeast Brazil experience[J]. J Surg Oncol, 2011, 104(3): 255-259.
4.	Potter C, Harris AL. Hypoxia inducible carbonic anhydraseⅨ, marker of tumour hypoxia, survival pathway and therapy target[J]. Cell Cycle, 2004, 3(2): 164-167.
5.	Robertson N, Potter C, Harris AL. Role of carbonic anhydraseⅨ in human tumor cell growth, survival, and invasion[J]. Cancer Res, 2004, 64(17): 6160-6165.
6.	Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases[J]. Cancer Res, 2000, 60(24): 7075-7083.
7.	Liao SY, Darcy KM, Randall LM, et al. Prognostic relevance of carbonic anhydrase-Ⅸ in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 16(3): 452-458.
8.	Woelber L, Kress K, Kersten JF, et al .Carbonic anhydraseⅨ in tumor tissue and sera of patients with primary cervical cancer[J]. BMC Cancer, 2011, 11(11): 12.
9.	Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface[J]. Nat Rev Cancer, 2004, 4(1): 45-60.
10.	Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease[J]. Physiol Rev, 2006, 86(1): 245-278.
11.	Gipson IK, Blalock T, Tisdale A, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence[J]. Biol Reprod, 2008, 78(1): 134-142.
12.	Togami S, Nomoto M, Higashi M, et al. Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix[J]. J Obstet Gynaecol Res, 2010, 36(3): 588-597.
13.	Sobti RC, Singh N, Hussain S, et al. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis[J]. J Recept Signal Transduct Res, 2010, 30(3): 178-188.
14.	Chen HH, Chou CY, Wu YH, et al. Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 658-666.
15.	Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy[J]. Cancer Sci, 2007, 98(9): 1336-1343.
16.	Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10): 983-991.
17.	Park JS, Jeon EK, Chun SH, et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer[J]. Gynecol Oncol, 2011, 120(2): 275-279.
18.	Hasegawa K, Kato R, Torii Y, et al. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage Ⅰ to stageⅡ uterine cervical adenocarcinoma[J]. Int J Gynecol Cancer, 2011, 21(8):1479-1485.
19.	Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell[M]. 5th ed. New York: Garland Science, 2008.
20.	Kim YI, Lee A, Lee BH, et al. Prognostic significance of syndecan-1 expression in cervical cancers[J]. J Gynecol Oncol, 2011, 22(3): 161-167.
21.	Shannan B, Seifert M, Leskov K, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer[J]. Cell Death Differ, 2006, 13(1): 12-19.
22.	Zellweger T, Chi K, Miyake H, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin[J]. Clin Cancer Res, 2002, 8(10): 3276-3284.
23.	Miyake H, Hara S, Arakawa S, et al. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma[J]. J Urol, 2002, 167(2 Pt 1): 703-706.
24.	He LR, Liu MZ, Li BK, et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma[J]. Cancer Sci, 2009, 100(12): 2354-2360.
25.	Watari H, Kinoshita R, Han Y, et al. Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy[J]. Int J Gynecol Cancer, 2012, 22(3): 465-470.
26.	Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells[J]. Nature, 2003, 423(6937): 302-305.
27.	Zhang X, Wang CX, Zhu CB, et al. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis[J]. Int J Gynecol Cancer, 2010, 20(9): 1597-1603.

1. 　Parkin DM, Bray F, Ferlay J, et al. Global Cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
2. 　Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world[J]. J Clin Oncol, 2006, 24(14): 2137-2150.
3. 　Bezerra AL, Martins MR, Bezerra SM, et al. ClassⅡ radical hysterectomy for stage Ⅰ-ⅡA cervix Cancer: prognostic factors associated to recurrence and survival in a Northeast Brazil experience[J]. J Surg Oncol, 2011, 104(3): 255-259.
4. 　Potter C, Harris AL. Hypoxia inducible carbonic anhydraseⅨ, marker of tumour hypoxia, survival pathway and therapy target[J]. Cell Cycle, 2004, 3(2): 164-167.
5. 　Robertson N, Potter C, Harris AL. Role of carbonic anhydraseⅨ in human tumor cell growth, survival, and invasion[J]. Cancer Res, 2004, 64(17): 6160-6165.
6. 　Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases[J]. Cancer Res, 2000, 60(24): 7075-7083.
7. 　Liao SY, Darcy KM, Randall LM, et al. Prognostic relevance of carbonic anhydrase-Ⅸ in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 16(3): 452-458.
8. 　Woelber L, Kress K, Kersten JF, et al .Carbonic anhydraseⅨ in tumor tissue and sera of patients with primary cervical cancer[J]. BMC Cancer, 2011, 11(11): 12.
9. 　Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface[J]. Nat Rev Cancer, 2004, 4(1): 45-60.
10. 　Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease[J]. Physiol Rev, 2006, 86(1): 245-278.
11. 　Gipson IK, Blalock T, Tisdale A, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence[J]. Biol Reprod, 2008, 78(1): 134-142.
12. 　Togami S, Nomoto M, Higashi M, et al. Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix[J]. J Obstet Gynaecol Res, 2010, 36(3): 588-597.
13. 　Sobti RC, Singh N, Hussain S, et al. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis[J]. J Recept Signal Transduct Res, 2010, 30(3): 178-188.
14. 　Chen HH, Chou CY, Wu YH, et al. Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2): 658-666.
15. 　Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy[J]. Cancer Sci, 2007, 98(9): 1336-1343.
16. 　Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10): 983-991.
17. 　Park JS, Jeon EK, Chun SH, et al. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer[J]. Gynecol Oncol, 2011, 120(2): 275-279.
18. 　Hasegawa K, Kato R, Torii Y, et al. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage Ⅰ to stageⅡ uterine cervical adenocarcinoma[J]. Int J Gynecol Cancer, 2011, 21(8):1479-1485.
19. 　Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell[M]. 5th ed. New York: Garland Science, 2008.
20. 　Kim YI, Lee A, Lee BH, et al. Prognostic significance of syndecan-1 expression in cervical cancers[J]. J Gynecol Oncol, 2011, 22(3): 161-167.
21. 　Shannan B, Seifert M, Leskov K, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer[J]. Cell Death Differ, 2006, 13(1): 12-19.
22. 　Zellweger T, Chi K, Miyake H, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin[J]. Clin Cancer Res, 2002, 8(10): 3276-3284.
23. 　Miyake H, Hara S, Arakawa S, et al. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma[J]. J Urol, 2002, 167(2 Pt 1): 703-706.
24. 　He LR, Liu MZ, Li BK, et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma[J]. Cancer Sci, 2009, 100(12): 2354-2360.
25. 　Watari H, Kinoshita R, Han Y, et al. Prognostic significance of clusterin expression in advanced-stage cervical cancer treated with curative intended radiotherapy[J]. Int J Gynecol Cancer, 2012, 22(3): 465-470.
26. 　Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells[J]. Nature, 2003, 423(6937): 302-305.
27. 　Zhang X, Wang CX, Zhu CB, et al. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis[J]. Int J Gynecol Cancer, 2010, 20(9): 1597-1603.

《華西醫學》

宮頸癌預后相關分子標志物的研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《華西醫學》

宮頸癌預后相關分子標志物的研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料